The Biomarkers have incredible potential to affect rate of success of clinical trials and identify new drug targets and advance diagnostic assays for early detection of disease. Biomarker development originates in the drug discovery phase and leads to clinical validation stage. In the target, discovery and validation stage biomarkers are used to identify and justify targets for therapy.
Biomarkers should have consistent characteristics with an acceptable sensitivity and specificity representing a specific toxicity or therapeutic effect of the drug, a specific physiological response to a treatment, a pathological progression, or a physiological factor.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Associations: International Pharmaceutical Federation, International Pharmaceutical Students Federation, Pharmaceutical Group of European Union (PGEU), Pharmaceutical Society of Australia.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
